A Study Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy.

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 18, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

February 28, 2026

Conditions

Diabetic Macular EdemaDiabetic Retinopathy

Interventions

DRUG

THN391 MAD

Route of administration- IVT injection

Trial Locations (2)

RECRUITING

Marsden Eye Specialists, Parramatta

NOT_YET_RECRUITING

Royal Adelaide Hospital, Adelaide

All Listed Sponsors

lead

Therini Bio Pty Ltd

INDUSTRY